Comment on ‘Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab'

Ítems similars

• Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
  per: Meyer, C H, et al.
  Publicat: (2011)
• Anti-VEGF Treatment Strategies for Wet AMD
  per: Kovach, Jaclyn L., et al.
  Publicat: (2012)
• Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
  per: Batioglu, Figen, et al.
  Publicat: (2015)
• Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania
  per: Stanca, Horia T., et al.
  Publicat: (2019)
• Improving treatment provision of Wet AMD with intravitreal ranibizumab
  per: Ghazala, Fadi, et al.
  Publicat: (2013)